Merck registers Phase 2b trial of tulisokibart for noninfectious uveitis
The trial, listed on ClinicalTrials.gov on 2026-10-06, will test tulisokibart against placebo in patients with active noninfectious intermediate, posterior, or panuveitis.
Merck Sharp & Dohme has a new registry entry for a study of its investigational drug tulisokibart in an eye inflammation condition.
- Tulisokibart (also known as MK-7240 or PRA023), a subcutaneous drug, is being evaluated in a Phase 2b trial for noninfectious intermediate, posterior, or panuveitis, with a status of "not yet recruiting" as of the first posted date. This trial will help researchers learn if tulisokibart, the trial medicine, can treat non-infectious intermediate, posterior, or panuveitis (NIIPPU) so that steroids can be given for a shorter period of time.1 The study plans to enroll 87 participants (estimated)1 and the primary goal is to learn if tulisokibart works better than placebo to increase the length of time until NIIPPU gets worse.1 The record lists an estimated start date of 2026-10-27 and estimated primary completion of 2029-06-05.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.